Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 07, 2025 04:00 ET | Source: AKAMPION

Next-generation RNA company Inverna Therapeutics launched by Argobio and University of Southern Denmark

Novel paradigm for therapeutics based on RNA splicing modulationLead program in Huntington’s disease Denmark – Odense – 07/01/2025 – Inverna Therapeutics, a novel Danish biotech company at the...
April 24, 2024 03:00 ET | Source: Harness Therapeutics

Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair

Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein...
February 07, 2024 08:00 ET | Source: Vaccinex, Inc.

Vaccinex Announces Pricing of $3.7 Million PIPE Financing

ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
November 28, 2023 04:00 ET | Source: Harness Therapeutics

Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases

Harness, formerly operating as Transine, broadens its approach to physiological protein upregulation through post-transcriptional modulation of protein synthesisRefined focus on neurodegenerative...
October 26, 2023 09:30 ET | Source: Vaccinex, Inc.

Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

ROCHESTER, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, today reports novel findings for its lead product, pepinemab, in a...
February 13, 2023 05:59 ET | Source: Fortune Business Insights

Huntington’s Disease Treatment Market Size to Hit USD 2,932.2 Million By 2030, at a CAGR of 17.5%

Pune, India, Feb. 13, 2023 (GLOBE NEWSWIRE) -- The global Huntington’s disease treatment market size reached USD 848.0 million in 2022. The market value is anticipated to increase from USD 945.8...
November 13, 2020 08:05 ET | Source: Vaccinex, Inc.

Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Additional data from SIGNAL Huntington’s disease (HD) trial support continued development in HD and in Alzheimer’s disease (AD) Phase 1/2 Study to Evaluate Pepinemab in Combination with KEYTRUDA®...
July 07, 2020 07:55 ET | Source: Vaccinex, Inc.

Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s Disease

ROCHESTER, N.Y., July 07, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease...
April 07, 2020 07:55 ET | Source: Vaccinex, Inc.

Vaccinex Delivers Virtual Presentation at the Advances in Alzheimer’s and Parkinson’s Therapies AAT-AD/PD™ Focus Meeting 2020

ROCHESTER, N.Y., April 07, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
September 09, 2016 09:45 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. Announces Continuation of the SIGNAL Clinical Trial

ROCHESTER, N.Y., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...